Finally, experience of trying to develop novel therapeutic brokers for these patients (see previous sections) leads to the conclusion that targeting one or even a few of the late-stage mediators is likely to deliver, at best, a therapeutic with limited efficacy, in a defined subpopulation of these patients – Structure-Based Design of mTORC1 Inhibitors in Cancer Therapy